Acotiamide hydrochloride hydrate

Phase 3Small molecule

ZZeria Pharmaceutical

Acotiamide hydrochloride hydrate is one of 35 small molecule programs targeting Dyspepsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaActive, not recruiting

DyspepsiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

99 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Phase 3

2 2

Tofranil

Sanofi

Phase 3

1 3

Elavil

AstraZeneca

Phase 3

1 4

Pamelor

SSpecgx

Phase 3

1 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Domperidone

Johnson & Johnson

Phase 3

3 7

Xifaxan

SSalix

Phase 2

3 8

Aciphex

Akero Therapeutics

Phase 2

1 9

Nereus

VVanda Pharmaceuticals

Phase 2

1 10

GW679769

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspepsia1 trial

A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia

Active, not recruiting·ZZeria Pharmaceutical·Phase 3·NCT04526119·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Acotiamide hydrochloride hydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acotiamide hydrochloride hydrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acotiamide hydrochloride hydrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zeria Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZeria Pharmaceutical

Acotiamide hydrochloride hydrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyspepsia1 trial

References

Drug Info

Quick Facts

Related News